Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2 | P10415 | 5/20 | 0.46 |
| ▸ | BCL2L1 | Q07817 | 2/20 | 0.46 |
| ▸ | DRD4 | P21917 | 3/20 | 0.41 |
| ▸ | DRD5 | P21918 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | DRD3 | P35462 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1540189 | 0.84 | BCL2 (0.48) | BCL2BCL2L1DRD4DRD5MAPT | |
| SCHEMBL1540186 | 0.84 | BCL2 (0.48) | BCL2BCL2L1DRD4DRD5MAPT | |
| SCHEMBL2959933 | 0.83 | BCL2L1 (0.47) | BCL2BCL2L1DRD4DRD5MAPT | |
| SCHEMBL1955370 | 0.83 | BCL2L1 (0.66) | BCL2BCL2L1DRD4 | |
| SCHEMBL2975749 | 0.82 | BCL2L1 (0.47) | BCL2BCL2L1DRD4DRD5MAPT | |
| SCHEMBL1111710 | 0.78 | NPC1 (0.40) | BCL2BCL2L1ALDH1A1KDM4EGAA | |
| SCHEMBL2973314 | 0.76 | BCL2L1 (0.60) | BCL2BCL2L1DRD4 | |
| SCHEMBL27629603 | 0.74 | MAPT (0.67) | DRD4DRD5MAPTALDH1A1LMNA | |
| SCHEMBL2968711 | 0.74 | BCL2L1 (0.48) | BCL2BCL2L1DRD4DRD5MAPT | |
| SCHEMBL1540934 | 0.67 | BCL2L1 (0.50) | BCL2BCL2L1DRD4DRD5MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1888543-B1 | APOPTOSIS PROMOTERS | ABBOTT LAB (US) | 2012-08-01 | — | — | EP | disclosed |
| US-7777076-B2 | Macrocyclic inhibitors of BCL proteins | ABBOTT LABORATORIES (US) | 2010-08-17 | — | — | US | disclosed |
| US-20080194691-A1 | Apoptosis Promoters | ABBOTT LABORATORIES (US) | 2008-08-14 | — | — | US | disclosed |
| EP-1888543-A1 | APOPTOSIS PROMOTERS | ABBOTT LABORATORIES (US) | 2008-02-20 | — | — | EP | disclosed |
| WO-2006127364-A1 | APOPTOSIS PROMOTERS | ABBOTT LABORATORIES (US) | 2006-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194691-A1 | Apoptosis Promoters | BAX, BCL2, BCOR | BCL2 2/4885BCL2L1 6/4885DRD4 3815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.